... marrow damage leading to different types of cancer.Targeted TherapyVarious targeted therapy drugs are used to treat ovarian cancer, including: Angiogenesis inhibitors such as Avastin (bevacizumab) PARP inhibitors, including Lynparza (olaparib) and Rubraca (rucaparib) TRK (tropomyosin receptor kinase) inhibitors, including Rozlytrek (entrectinib) and Vitrakvi ...
Stage 4 Ovarian Cancer Explained
... marrow damage leading to different types of cancer.Targeted TherapyVarious targeted therapy drugs are used to treat ovarian cancer, including: Angiogenesis inhibitors such as Avastin (bevacizumab) PARP inhibitors, including Lynparza (olaparib) and Rubraca (rucaparib) TRK (tropomyosin receptor kinase) inhibitors, including Rozlytrek (entrectinib) and Vitrakvi ...
... NTRK inhibitors block this process.Examples of NTRK inhibitors used for certain cancers with an NTRK gene fusion include: Entrectinib (Rozlytrek) Larotrectinib (Vitrakvi) Repotrectinib (Augtyro) Antibody-Drug ConjugatesIn 2024, the U.S. Food and Drug Administration (FDA) gave full approval to mirvetuximab soravtansine (Elahere) for ovarian cancer. ...
7 Ovarian Cancer Treatment Options
... NTRK inhibitors block this process.Examples of NTRK inhibitors used for certain cancers with an NTRK gene fusion include: Entrectinib (Rozlytrek) Larotrectinib (Vitrakvi) Repotrectinib (Augtyro) Antibody-Drug ConjugatesIn 2024, the U.S. Food and Drug Administration (FDA) gave full approval to mirvetuximab soravtansine (Elahere) for ovarian cancer. ...